Infex Therapeutics is focused on developing innovative anti-infective therapies to address the growing challenge of drug-resistant infections. The company has a diverse pipeline that includes several promising candidates aimed at treating critical-priority infectious diseases. Notably, their lead candidate, RESP-X, is a first-in-class anti-virulence antibody designed to target chronic Pseudomonas aeruginosa infections in respiratory diseases, particularly for patients with Non-Cystic Fibrosis Bronchiectasis. This drug aims to reduce the frequency of debilitating exacerbations, addressing a significant unmet medical need in this patient population. Additionally, Infex is developing MET-X, a metallo-beta-lactamase inhibitor that seeks to restore the efficacy of beta-lactam antibiotics against resistant bacterial strains, and COV-X, a novel antiviral candidate targeting coronaviruses with pandemic potential.

The company operates from Alderley Park in the North West of England, where it is well-positioned to advance its clinical trials and drug development efforts. Infex Therapeutics is committed to combating the global health crisis posed by antimicrobial resistance, which is projected to have severe implications for public health and economic stability in the coming decades. By acquiring, developing, and licensing new therapies, Infex aims to bring vital new drugs to market that can effectively treat life-threatening infections and improve patient outcomes.

United Kingdom

We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.

Infex Therapeutics

Company Details